Gapping up
In reaction to strong earnings/guidance:
- MIK +19.8%, COUP +12%, NAV +9.3%, GSM +4%, MCHP +1.5%
Other news:
- SENS +10.9% (announces two positive Blue Cross Blue Shield coverage decisions for Eversense continuous glucose monitoring)
- RARE +10.3% (announces positive data from second dose cohort of ongoing Phase 1/2 study of DTX401 for the treatment of glycogen storage disease type Ia)
- PBYI +9.4% (NERLYNX granted FDA Orphan Drug Designation for the treatment of breast cancer patients with brain metastases)
- BOX +8.2% (Starboard discloses 7.5% active stake)
- RARX +5.8% (FDA granted Orphan Drug Designation to zilucoplan for the treatment of myasthenia gravis)
- OMI +5.4% (extending today's climb higher)
- ACB +3.2% (disposes of remaining 28,833,334 shares of The Green Organic Dutchman Holdings for aggregate gross proceeds of $86.5 mln)
- FTV +3.2% (to separate into two independent, publicly traded companies)
- SVM +2.7% (reports increased reserves and resources at the Gaocheng Mine)
- CWH +2.7% (approved plan to strategically shift away from locations where the Company does not have the ability or where it is not feasible to sell and/or service RVs)
- TPR +2.5% (names Chairman Jide Zeitlin as CEO; guidance reaffirmed)
- TGH +1.4% (authorized $25 mln share repurchase program)
- MYOV +1% (staging another unusual after hours move; scheduled to present at several conferences this month), .
Analyst comments:
- STMP +2.8% (upgraded to Neutral from Sell at ROTH Capital)
- ATVI +2.7% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- CDTX +2.6% (upgraded to Outperform from Neutral at Wedbush)
- TRIP +2.1% (upgraded to Neutral from Sell at UBS)
- ROKU +1.9% (target raised to Street high $185 from $135 at DA Davidson)
- CPB +0.9% (upgraded to Neutral from Underweight at Piper Jaffray)
- EBS +0.9% (upgraded to Outperform from Market Perform at Wells Fargo)